ÂÜÀòÂÒÂ×

Rachel Williams is an accomplished professional in the field of clinical assays and biomarker development, currently serving as Director at BridgeBio Gene Therapy since July 2021, following a role as Associate Director. Previously, Rachel held positions at PRA Health Sciences, where responsibilities included method development for large and small molecules, project management, and authoring key documentation. Rachel's earlier experience includes research scientist roles at KCAS and Rowe Neurology Institute, focusing on project management and collaborative research in Multiple Sclerosis, respectively. Academic achievements include a PhD in Molecular & Integrative Physiology from the University of Kansas Medical Center and an MBA from the University of Kansas - Graduate School of Business.